Roivant — Q2 2026 Earnings Summary

Roivant reported $31.0 million in net product revenue from LISRAYA during its first five weeks of commercial launch in August 2026. The company announced that IMVT-1402 met its primary endpoint in a Phase 3 trial for difficult-to-treat rheumatoid arthritis, while brepocitinib successfully completed Phase 3 trials for non-infectious uveitis with a supplemental New Drug Application expected in early 2027. Additionally, mosliciguat demonstrated positive results in a Phase 2 study for pulmonary hypertension associated with interstitial lung disease, initiating a Phase 3 trial. Roivant's consolidated cash, cash equivalents, and marketable securities totaled $4.2 billion as of September 30, 2026, supported by a $950 million payment received from Moderna.